RITUXIMAB
|
INFLIXIMAB
|
ETANERCEPT |
ADALIMUMAB |
ANAKINRA |
|
|---|---|---|---|---|---|
Lupus |
B |
D |
D |
D |
|
Sjogren |
C |
A |
A |
||
APS |
D |
||||
PM |
D |
D |
D |
||
DM |
C |
D |
D |
D |
|
PAN |
D |
||||
Wegener |
C |
C |
A |
||
Churg-Strauss |
D |
D |
D |
||
PAM |
D |
C |
|||
Crioglobulinemi |
C |
D |
D |
||
Behçet |
C |
A |
C |
||
Sarcoidosis |
D |
C |
C |
D |
D |
Still |
D |
A |
A |
D |
|
Scleroderma |
D |
D |
C |
D |
|
Policondritis |
D |
D |
Evidence Level
| Categories | Randomization | Control | Design | Follow-up | Type of study |
|---|---|---|---|---|---|
A |
Yes |
Yes |
Experimental |
Prospective |
Clinical trial |
B |
No |
Yes |
Experimental |
Prospective |
Clinical trial |
C |
No |
No |
Observational |
Prospective |
Open-label trial |
D |
No |
No |
Observational |
Retrospective |
Case report |
Definitions of the use of biological therapies
Indications for the use of each biological drug in each of the SAD was categorized in three levels according to the global percentage of response:
| Indicated: drugs with a percentage of response in more than 50% of reported cases. |
| Precaution: drugs with a percentage of response between 10% and 50% of reported cases. |
| Not recommended: drugs with a percentage of response lower than 10% of reported cases or those drugs reported to produce excess side effects. |